CLUSTER-TIL Harnessing Heterotypic T Cell Clusters to Boost Til Cancer Therapy
- Coordinator
- Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek Ziekenhuis, Netherlands
- Runs
- 1 September 2026 to 29 February 2028
- Status
- Running
- EU funding
- €150k
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101335229
What the project is doing
In the project's own words, from its summary on CORDIS.
Despite major advances in cancer immunotherapy, most patients still lack durable benefit. Tumor-infiltrating T lymphocyte (TIL) therapy can induce deep cancer remissions, but potency varies and complete clinical responses are limited to 20%. Crucially, although truly tumor-reactive T cells are rare in cancers (<5%), current manufacturing protocols expand TILs in bulk, without inclusion of a selection or enrichment step.
Together, these observations create both a dire clinical need and unique opportunity to augment the impact of this type of immunotherapy, namely by selecting the actively tumor-killing T cells. In our current ERC Advanced project ReverT, we discovered that tumor-killing T cells are strongly enriched in so-called heterotypic cell clusters: tight conjugates of T cells with tumor (melanoma) cells and/or antigen-presenting cells.
We developed an isolation procedure to capture intact clusters straight from clinical cancer specimens from patients. These T cell clusters can be effectively expanded and exhibit a 9-fold increase in tumor-killing activity against patient tumors. This ERC PoC project translates our findings into a “CLUSTER-TIL” manufacturing module, integrating upstream of the standard production pipeline to enable enhanced TIL therapy.
We will develop and optimize a scalable procedure to purify cluster-derived T cells from tumor digests from patients, define quality metrics for tumor reactivity and benchmark to the standard bulk TIL workflow. CLUSTER-TIL will deliver a highly potent, consistent anti-cancer T cell therapy that will be tested in a planned investigator-initiated Phase 2a trial in melanoma. We observe similar clusters in other solid tumor types, enabling expansion to patient groups beyond melanoma.
Furthermore, two patent applications protect the CLUSTER-TIL technology. This PoC will also generate follow-on IP to support a spin-off applying the technology for broader clinical implementation and improved patient outcomes.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek Ziekenhuis | Amsterdam | Netherlands | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI